Rôle des interactions entre les dérivés réactifs de l'oxygène et le microbiome intestinal dans la pathophysiologie de la maladie inflammatoire de l'intestin des patients ayant un déficit immunitaire primaire


Emilia Liana Falcone

Institut de recherches cliniques de Montréal [IRCM]


Domaine : maladies infectieuses et immunitaires

Programme Chercheurs-boursiers cliniciens - Junior 1

Concours 2018-2019

Almost 3 million people suffer from inflammatory bowel disease (IBD) in North America. IBD is a chronic inflammation of the gut that causes symptoms such as cramping, diarrhea and weight loss. It is challenging to treat and IBD therapies often cause significant side-effects. While IBD is generally viewed as a disease of the western world, it is rapidly becoming a global epidemic due to shifts in environmental exposures and diet. Shifts in diet and exposure to different chemicals and medications can cause changes to the community of microbes that normally live in our gut. This community of microbes is called the microbiome and increasing studies are showing that shifts in the gut microbiome can greatly affect inflammation both in the gut and elsewhere in the body. There are groups of individuals that suffer from rare diseases called PIDs, which stands for primary immune deficiency. This is a general term that includes many different inherited immune system disorders. The immune system is the part of the body that helps fight disease and infection. People with PIDs can develop many kinds of health problems. One of these is IBD.

We think that patients with PIDs have unique shifts in their gut microbiome that may increase their chances at developing IBD. The study of the gut microbiome in patients with PIDs (through the examination of their stool) may help us better understand the connection between the microbiome, the immune system and development of IBD. The goal of our research program is therefore to study patients with PIDs and IBD in order to better understand the contribution of the gut microbiome and immune system to the development of IBD in general. We believe that our findings could help us uncover new therapies to treat IBD in both patients with and without PIDs.